FY2029 Earnings Forecast for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Analysts at HC Wainwright issued their FY2029 EPS estimates for Q32 Bio in a research note issued to investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.18) per share for the year. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s FY2030 earnings at $0.11 EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.00.

Q32 Bio Stock Up 0.6%

Shares of NASDAQ QTTB opened at $4.76 on Thursday. Q32 Bio has a fifty-two week low of $1.35 and a fifty-two week high of $6.37. The business has a 50 day moving average price of $3.78 and a two-hundred day moving average price of $2.88. The firm has a market cap of $58.55 million, a PE ratio of -1.38 and a beta of 0.16.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new position in Q32 Bio in the first quarter valued at about $68,000. Goldman Sachs Group Inc. grew its stake in shares of Q32 Bio by 140.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock valued at $73,000 after buying an additional 25,953 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Q32 Bio in the first quarter worth approximately $50,000. Monaco Asset Management SAM raised its position in Q32 Bio by 17.1% during the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock valued at $882,000 after acquiring an additional 86,486 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Q32 Bio in the second quarter valued at approximately $25,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Lee Kalowski sold 9,072 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $3.46, for a total transaction of $31,389.12. Following the completion of the sale, the chief financial officer directly owned 39,938 shares of the company’s stock, valued at $138,185.48. This represents a 18.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jodie Pope Morrison sold 22,506 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $77,870.76. Following the sale, the chief executive officer directly owned 99,000 shares of the company’s stock, valued at approximately $342,540. This represents a 18.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 40.00% of the stock is owned by company insiders.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.